产妇抗脂综合征 产妇抗脂综合征
Adriana Soto-Peleteiro1, Cristina Gonzalez-Echavarri1, Guillermo Ruiz-Irastorza2
1Autoimmune Diseases Research Unit, Department of Internal Medicine, Biobizkaia Health Research Institute, Hospital Universitario Cruces, Spain.
概括
怀孕期间抗脂综合征 (APS) 管理需要早期的医疗-产科协调. 治疗包括低剂量阿司匹林和潜在的低分子量肝素,以预防妊娠并发症.
科学领域:
- 产科和妇科 产科和妇科
- 类风湿病学 类风湿病学
- 血液学 血液学 血液学
背景情况:
- 抗脂综合征 (APS) 是一种主要的自身免疫性血栓友症.
- APS显著增加了不良妊娠结果的风险,包括流产和胎盘功能障碍.
- 在APS怀孕中,有效的管理对于改善母亲和胎儿健康至关重要.
研究的目的:
- 概述产科抗脂综合征 (APS) 的基本管理策略.
- 强调怀孕前咨询和风险评估的重要性.
- 在怀孕和产后期间详细介绍APS的治疗方法.
主要方法:
- 审查当前的文献和临床指南产科APS管理.
- 强调涉及医疗和产科专家的多学科方法.
- 讨论药理干预和交付时间方面的考虑.
主要成果:
- 怀孕前访问对于风险分层和治疗调整至关重要.
- 低剂量阿司匹林与低分子量肝素相结合是APS妊娠管理的基石.
- 除非出现并发症,否则不建议常规诱导分娩.
结论:
- 从怀孕前开始的协调医疗产科护理对于在怀孕期间管理APS至关重要.
- 个性化治疗策略可以改善受APS影响的怀孕的结果.
- 产后管理是全面的APS护理的关键组成部分.
相关概念视频
Phosphoinositides and PIPs
8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
Pathophysiology of Diabetes
908
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
908
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Asymmetric Lipid Bilayer
7.2K
Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...
7.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162


